标题: PharmaTher's 3D Printed Medicine Roadmap Targets 50 CraftMake Systems Within 12 Months [打印本页] 作者: admin 时间: 2026-10-12 17:16 标题: PharmaTher's 3D Printed Medicine Roadmap Targets 50 CraftMake Systems Within 12 Months On October 10, 2026, Nanjixiong learned that Canadian pharmaceutical company PharmaTher Holdings had announced a multiyear roadmap for 3D printed medicines. It plans to accept the first CraftMake pharmaceutical 3D printer orders in the fourth quarter of 2026 and has renamed its PERSONALIZ3D platform M3DICINES.
On October 1, PharmaTher confirmed that it had become the exclusive North American distributor of the CraftMake system developed by Singapore's Craft Health. The company plans to deploy up to 50 printers in North America within 12 months, serving pharmacies, telehealth providers, CDMOs, hospitals, research institutions and government facilities. Potential installation sites exceed 10,000.
Its product plans include 3D printed chewable and orally dissolving tablets containing NAD+ and glutathione this quarter, followed by orally dissolving ketamine tablets for telehealth in the first quarter of 2027. It is also developing orally dissolving tablets for rare pediatric diseases, with a new drug application (NDA) planned for the fourth quarter of 2028. Approval could provide seven years of orphan drug exclusivity.
Nanjixiong's observation
3D printed medicines are moving from laboratories toward distributed manufacturing networks. Economical production of small batches and patient-specific doses is a core advantage, while regulatory acceptance of on-demand printed doses will influence the rate of scaling.
AI-translated from an article by Kuaixiong on Nanjixiong, originally published on 2026-10-10. Text and images retain the original source attribution. Read the original Chinese article
欢迎光临 All Voice of China 3D Printing (https://panda3dp.com/)